<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875873</url>
  </required_header>
  <id_info>
    <org_study_id>basics001</org_study_id>
    <nct_id>NCT02875873</nct_id>
  </id_info>
  <brief_title>Balanced Solution Versus Saline in Intensive Care Study</brief_title>
  <acronym>BaSICS</acronym>
  <official_title>Balanced Solution Versus Saline in Intensive Care Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2x2 factorial randomized study to evaluate the effect of a balanced crystalloid solution&#xD;
      compared with 0.9% saline, and of rapid vs. slow infusion on clinical outcomes of critically&#xD;
      ill patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pragmatic, multicenter, 2x2 factorial randomized study. Severe patients admitted to the ICU&#xD;
      at moderate to high risk for death or acute kidney injury will be randomly allocated to&#xD;
      receive a balanced crystalloid solution (Plasma-Lyte®) or 0.9% saline and to receive&#xD;
      crystalloids by rapid bolus infusion (999 mL/h) or slow infusion (333 mL/h) whenever plasma&#xD;
      expansion is needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2017</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">March 2, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal failure requiring renal replacement therapy</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Injury (KDIGO equal or greater than 2)</measure>
    <time_frame>Days 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic, cardiac, neurological, coagulation, and respiratory dysfunctions (assessed by Sequential Organ Failure Assessment [SOFA] scores)</measure>
    <time_frame>Days 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Intensive Care Unit Mortality</measure>
    <time_frame>At ICU discharge, up to 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>At Hospital discharge, up to 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of Intensive Care Unit stay</measure>
    <time_frame>At ICU discharge, up to 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>At hospital discharge, up to 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life at 6 months</measure>
    <time_frame>180 days</time_frame>
    <description>Assessed using EQ-5D. Will only be performed in a subsample of all included patients (10%)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">11075</enrollment>
  <condition>Critical Illness</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Plasma-Lyte, Slow Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma-Lyte, Fast Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline 0.9%, Slow Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline 0.9%, Fast Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasma-Lyte</intervention_name>
    <description>Plasma-Lyte will be used for fluid expansion and maintenance</description>
    <arm_group_label>Plasma-Lyte, Fast Infusion</arm_group_label>
    <arm_group_label>Plasma-Lyte, Slow Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9%</intervention_name>
    <description>Saline 0.9% will be used for fluid expansion and maintenance</description>
    <arm_group_label>Saline 0.9%, Fast Infusion</arm_group_label>
    <arm_group_label>Saline 0.9%, Slow Infusion</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Slow infusion speed</intervention_name>
    <description>Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.</description>
    <arm_group_label>Plasma-Lyte, Slow Infusion</arm_group_label>
    <arm_group_label>Saline 0.9%, Slow Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fast Infusion Speed</intervention_name>
    <description>Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.</description>
    <arm_group_label>Plasma-Lyte, Fast Infusion</arm_group_label>
    <arm_group_label>Saline 0.9%, Fast Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all three):&#xD;
&#xD;
          1. Need for plasma expansion, and the clinician considers that Plasma-Lyte® or 0.9%&#xD;
             saline are equally appropriate for patients, with no specific indications or&#xD;
             contraindications for any of the fluids or for rapid or slow infusion.&#xD;
&#xD;
          2. Patients not expected to be discharged on the day after their admission.&#xD;
&#xD;
          3. At least one of the following risk factors for acute renal injury:&#xD;
&#xD;
               1. Age ≥ 65 years&#xD;
&#xD;
               2. Hypotension (mean arterial pressure [MAP] &lt; 65 mmHg or systolic blood pressure&#xD;
                  [SBP] &lt; 90 mmHg) or use of vasopressors&#xD;
&#xD;
               3. Sepsis&#xD;
&#xD;
               4. Use of invasive mechanical ventilation or of continuous noninvasive mechanical&#xD;
                  ventilation (including high-flow nasal cannula) &gt; 12 hours&#xD;
&#xD;
               5. Oliguria (&lt; 0.5 mL/kg/hour for ≥ 3 hours)&#xD;
&#xD;
               6. Serum creatinine ≥ 1.2 mg/dL for women or ≥ 1.4 mg/dL for men&#xD;
&#xD;
               7. Liver cirrhosis or acute liver failure&#xD;
&#xD;
        Exclusion Criteria (any of the below):&#xD;
&#xD;
          1. Age &lt; 18 years&#xD;
&#xD;
          2. Acute renal failure treated with renal replacement therapy (RRT) or expected to&#xD;
             require RRT within the next 6 hours&#xD;
&#xD;
          3. Severe hyponatremia (serum sodium ≤ 120 mmol/L)&#xD;
&#xD;
          4. Severe hypernatremia (serum sodium ≥ 160 mmol/L)&#xD;
&#xD;
          5. Death considered imminent and inevitable within 24 hours&#xD;
&#xD;
          6. Patients with suspected or confirmed brain death&#xD;
&#xD;
          7. Patients under exclusive palliative care&#xD;
&#xD;
          8. Patients previously enrolled in the BaSICS study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre B Cavalcanti, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando G Zampieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nilton Brandao, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Moinhos de Vento</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flávia R Machado, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidade Federal de São Paulo, UNIFESP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodrigo S Biondi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Cardiologia do Distrito Federal, ICDF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flávio G Rezende de Freitas, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidade Federal de São Paulo, Departamento de Cirurgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alexandre Biasi Cavalcanti</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04005000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be publicly available two years after trial results have been published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

